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Abstract: The impact on health care of patients with myelodysplastic syndromes (MDS) is continuously
rising. To investigate the perception of hemato-oncologists concerning the recommended MDS
patient care in Switzerland, we conducted a web-based survey on diagnosis, risk-stratification
and treatment. 43/309 physicians (13.9%) replied to 135 questions that were based on current
guidelines between 3/2017 and 2/2018. Only questions with feedback-rates >50% were further
analysed and ratios >90% defined “high agreement”, 70–90% “agreement”, 30–70% “insufficient
agreement” and <30% “disagreement”. For diagnosis, we found insufficient agreement on using
flow-cytometry, classifying MDS precursor conditions, performing treatment response assessment
after hypomethylating agents (HMA) and evaluating patients with suspected germ-line predisposition.
For risk-stratification, we identified agreement on using IPSS-R but insufficient agreement for IPSS
and patient-based assessments. For treatment, we observed disagreement on performing primary
infectious prophylaxis in neutropenia but agreement on using only darbepoetin alfa in anaemic,
lower-risk MDS patients. For thrombopoietin receptor agonists, insufficient agreement was found for
the indication, preferred agent and triggering platelet count. Insufficient agreement was also found
for immunosuppressive treatment in hypoplastic MDS and HMA dose adjustments. In conclusion,
we identified areas for improvement in MDS patient care, in need of further clinical trials, information,
and guiding documents.
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1. Introduction
Guidelines and recommendations (G/Rs) for the diagnostic work-up and treatment of adult
patients with myelodysplastic syndromes (MDS) are published [1–3]. However, the level of adherence
in the daily clinical practice remains unclear, both in Switzerland and in many other countries.
MDS represent a heterogeneous group of hematopoietic stem cell disorders with a variable risk
of transformation into secondary acute myeloid leukemia (AML). The syndromes are diagnosed at
a median age above 70 years and characterized by cytopenias, dysplasia and inflammation [4,5].
Due to aging of the population and the integration of next generation sequencing (NGS) in the
diagnostic evaluation of unclear cytopenias, we are observing an increase of MDS cases in recent years.
The heterogeneity of the disease, complexity of management and multi-morbidity of the mainly elderly
MDS patients leads to an increasing burden on health care systems with the risk for inappropriate use
of resources [4,5].
Adherence to G/Rs is generally considered as good quality of care and a cornerstone for
appropriate health service [6,7]. Hence, national and international, evidence-based guidelines for
diagnosis and therapy of adult MDS have been published, in order to assist clinicians in their daily
decision-making [1–3]. However, publishing G/Rs does not necessarily translate into better quality
of care, if adherence to G/Rs is not implemented and maintained into daily routine [7,8]. Numerous
studies have highlighted the difficulties to follow clinical practice guidelines, with non-adherence
reaching up to 70% across most disciplines and countries [9–11]. Population-based registries and
cohorts revealed that around one quarter of MDS patients did not receive the required bone marrow
cytogenetics analysis [12–17], which impedes appropriate risk calculation by IPSS or IPSS-R. Similarly,
the iron status and the endogenous EPO-level were determined in only half of patients receiving
erythropoiesis-stimulating agents (ESA) [12,15,18]. This implies that many lower-risk MDS patients
receive ESA without complete assessment and estimation of their chance for response. Retrospective
studies have shown general shortcomings in adherence to recommended health care procedures [19,20].
Recently, a pro and retrospective analysis of MDS patients treated in a tertiary care center in Germany
showed that adherence to G/Rs for allogeneic hematopoietic stem cell transplantation (allo HSCT)
resulted in improved survival [21]. However, a systematic investigation of the level of adherence,
potential reasons for non-adherence and the impact on other outcomes than survival has not been
performed so far.
Here, we surveyed the perception of hemato-oncologists on how appropriate diagnostics,
risk-stratification and treatment should be provided to adult MDS patients in Switzerland and
compared their feedbacks to currently published G/Rs.
2. Methods
2.1. Study Design
We performed a survey among physicians between 3/2017 and 2/2018. The survey was initiated
by the Swiss MDS Study Group (SMSG), an independent, research consortium of hemato-oncologists
practicing in Switzerland. It received funding by grants from public institutions, which did not have
any influence on the design and interpretation of the results. Approval from the regional ethics
committee was not required.
2.2. Participants
Participants were recruited either by e-mail through the SMSG and the Swiss Society of Hematology
(SSH) or personally during educational conferences. From 309 hematologists and oncologists registered
at SSH, 42 practicing in Switzerland and one in Germany replied to our survey. The characteristics of
the participants are summarized in Table 1. Most participants were younger than 50 years (30/43, 70%)
and received their board certification after 2000 (29/43, 67%). Three quarters worked in secondary
or tertiary centers (32/43, 74%) with 84% (36/43) being members of the SSH and 58% (25/43) of the
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European Hematology Association (EHA). Most were familiar with ELN 2013 MDS recommendations
for diagnosis (38/43, 88.4%) and treatment (37/43, 86%) [1].
Table 1. Characteristics of participants.
Total 43 (100%)
Age-categories
30–40 years 10 (23.2%)
41–50 years 20 (46.5%)
51–60 years 9 (20.9%)
61–70 years 2 (4.7%)
Missing 2 (4.7%)






General practice 1 (2.3%)
Specialised practice 5 (11.6%)
Primary center 5 (11.6%)
Secondary center 14 (32.6%)










Agreement with ELN 2013 recommendations for diagnosis of MDS(1)
Yes 38 (88.3%)
No 2 (4.7%)
Not familiar 3 (7%)
Agreement with ELN 2013 recommendations for treatment of MDS(1)
Yes 37 (86%)
No 2 (4.7%)
Not familiar 3 (7%)
Missing 1 (2.3%)
ASH: American Society of Hematology, DGHO: German Society of Hematology and Medical Oncology,
EHA: European Hematology Association, SSH: Swiss Society of Hematology, SSMO: Swiss Society of Medical
Oncology, SMSG: Swiss MDS Study Group.
2.3. Survey Design
The survey was designed on the REDCap system [22]. It was composed of 135 multiple-choice
questions covering the whole spectrum of MDS patient care and based on the recommendations from
the European Leukemia Net (ELN) 2013 MDS guideline, from 3/2017 until 2/2018 [1]. The questions
comprised the three domains of diagnostic evaluation (n = 18), risk-stratification (n = 12) and treatment,
including supportive care (n = 21), growth factors (n = 22), disease modifying treatment (imids,
immune modulating agents, hypomethylating agents) (n = 40) and allo HSCT (n = 22).
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2.4. Data Collection
The survey was submitted by e-mail and contained general information on the background,
aims and performance of the survey including a link to the web-based survey. From all contacted
physicians (n = 309), we received a feedback from 43 participants (overall feedback-rate 13.9%).
2.5. Data Processing and Evaluation
After closure of the survey, data was directly exported from REDCap. In a first step, we evaluated
in how far the feedbacks were representative. From the 43 participants, we defined an optimal
feedback-rate >75%, whereas 50–75% was defined as sufficient and <50% insufficient for further
analysis. Questions regarding allo HSCT were considered separately, as only six participants were
involved in this type of treatment. 41 out of 135 questions (30.4%) had an insufficient feedback-rate
and were excluded from further evaluation (Supplementary Materials Table S1). The agreement
score for each representative question was determined by the ratio of all participants who selected
the corresponding item. We defined >90% as “high agreement”, 70–90% as “agreement”, 30–70% as
“insufficient agreement”, and <30% as “disagreement”.
2.6. Data Representation and Statistics
We used descriptive statistics for the representation and analysis of results. Discrete variables are
presented as absolute and relative numbers, continuous variables are shown as intervals and median
values for the comparison between different patient groups.
3. Results
3.1. Diagnostic Evaluation
We received sufficient feedbacks (>50% of all participants) for 17 of 18 questions (94%) in this
domain, while only the question on single gene analysis had to be dropped (Table 2 and Supplementary
Materials Table S1). We observed high agreement in using the most recent revision of the World
Health Organization 2016 classification system for diagnosis of MDS and its subtypes [23]. In contrast,
agreement was insufficient regarding the use of the diagnostic terms of “clonal hematopoiesis of
indeterminate potential” (CHIP), “clonal cytopenia of unknown significance” (CCUS), and “idiopathic
cytopenia/dysplasia of unknown significance” (ICUS/IDUS (29/43, 67.4%) [24]. There was high
agreement on the need of bone marrow (BM) examination at suspected diagnosis (43/43, 100%) and
progression (and 40/43, 93%), while insufficient agreement was found on the assessment of response to
hypomethylating agents (HMA) (20/43, 46.5%). Participants agreed that the inter-observer variability
for the morphological quantification of blasts is acceptable (31/43, 72.1%) but their agreement was
insufficient concerning an acceptable inter-observer variability for the morphological assessment of
dysplasia (24/43, 55.8%). We found full agreement on the need of cytogenetic examination at suspected
diagnosis (43/43, 100%), agreement at progression (35/43, 81.4%), but disagreement on its use to assess
response to HMA (9/43, 20.9%). Insufficient agreement was also found on the use of Fluorescent In-Situ
Hybridization (FISH) panel (21/43, 48.8%) or array-Comparative Genomic Hybridization (array-CGH)
in patients with normal karyotype (17/43, 39.5%). Agreement was found on performing molecular
diagnostic (37/43, 86%) with comprehensive myeloid gene panels (29/37, 78.4%). In contrast, agreement
was insufficient regarding the need for flow cytometry (28/43, 65.1%). While most participants were
aware of the hereditary AML/MDS syndromes (33/43, 76.7%), there was insufficient agreement on the
requirement to record a pedigree (23/33, 69.7%) and disagreement on using a systematic screening
questionnaire (2/33, 6%) [25] as well as referring to genetic counseling (7/33, 21.2%) in suspicious cases
of younger MDS patients.
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Table 2. Diagnostic evaluation.
Questions Feedback Performance
1. Classification
MDS classification system 43 (100%)
WHO 2016 ([23]): 41 (95.3%)
WHO 2008 ([26]): 12 (27.9%)
FAB ([27]): 3 (7%)
Use of the diagnostic terms ICUS, IDUS, CCUS or CHIP [24] 43 (100%) Yes: 29 (67.4%)No: 14 (32.6%)
2. Bone Marrow (BM)
Time of the BM assessment 43 (100%)
At (suspected) diagnosis: 43 (100.0%)
At (suspected) progression: 40 (93.0%)
To access response to hypomethylating agents
(HMAs): 20 (46.5%)
Who evaluates BM smears at your institution? 43 (100%) Hematologist: 41 (95.3%)Pathologist: 10 (23.3%)
Acceptable inter-observer variability of morphological signs
of dysplasia 43 (100%)
Yes: 24 (55.8%)
No: 19 (44.2%)
Does morphological quantification of blasts have an




When should karyotyping be performed? 43 (100%)
At (suspected) diagnosis: 43 (100.0%)
At (suspected) progression: 35 (81.4%)
To assess response to hypomethylating agents
(HMAs): 9 (20.9%)
Necessity of analysis with an MDS FISH panel in MDS




Should array-CGH replace MDS FISH panels in MDS patients





Do you use molecular diagnostics for MDS? 43 (100%) Yes: 37 (86.0%)No: 6 (14.0%)
What type of gene panel do you use for diagnosis? 37 (86%)
Comprehensive myeloid driver gene panel
(>10 genes): 29 (78.4%)
Undecided: 5 (13.5%)
Only single gene analysis: 3 (8.1%)
Reduced myeloid driver gene panel: 0 (0.0%)
5. Flow Cytometry
Do you use flow cytometry for MDS diagnosis? 43 (100%) Yes: 28 (65.1%)No: 15 (34.9%)
Do you use the OGATA flow cytometry score for
MDS diagnosis [28]? 28 (65.1%)
Yes: 18 (64.3%)
I am not familiar with OGATA flow score: 5 (17.9%)
No: 4 (14.3%)
I am using another flow score: 1 (3.6%)
6. Germ Line Predisposition
Are you aware of hereditary AML/MDS syndromes? 43 (100%) Yes: 33 (76.7%)No: 10 (23.3%)
Do you record a pedigree for patients with suspected
hereditary AML/MDS syndromes? 33 (76.7%)
Yes: 23 (69.7%)
No: 10 (30.3%)
Do you use a questionnaire for the screening of patients with
suspected hereditary AML/MDS syndromes [25]? 33 (76.7%)
No: 31 (93.9%)
Yes: 2 (6.1%)
Have you ever referred a patient to genetic counseling due to




We received sufficient feedbacks for 10 of 12 questions (83%) in this domain, while questions
about quality of life and geriatric assessment tools had to be dropped (Table 3 and Supplementary
Materials Table S1). There was high agreement on applying risk-stratification with disease-based risk
scores (40/42, 95.2%), whereas only about half of the participants (23/43, 54.8%) used patient-based
risk scores. Most of the survey participants agreed on applying disease-based risk scores at
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diagnosis (41/42, 97.7%) and progression (31/42, 73.8%), while only about half agreed in using them
at transplantation (24/42, 57.1%). The 23 participants, using patient-based risk-stratification, did it
preferentially at diagnosis (78.2%) and transplantation (74%) but without a preference for a specific
score. There was high agreement on using the Revised International Prognostic Scoring System (R-IPSS)
(41/42, 97.6%) with insufficient agreement on the IPSS (28/42, 66.7%), the WHO-prognostic Scoring System
(WPSS) (19/42, 45.2%) and the hypoplastic MDS prognostic risk score (18/39, 46.2%) for disease-based
risk-stratification. Finally, we found disagreement on using tools for combined risk-stratification,
for geriatric as well as quality of life (QoL) assessment.
Table 3. Risk-stratification.
Questions Feedback Performance
Should assessment of disease- and





When do you use disease-based
risk-stratification scores in MDS patients? 42 (97.7%)
At diagnosis: 41 (97.6%)
At progression: 31 (73.8%)
At transplantation: 24 (57.1%)
Other time points: 1 (2.4%)
Not at all: 0 (0.0%)
Which of the following scores do you use for
disease-based risk-stratification? 42 (97.7%)
R-IPSS/IPSS-R [29]: 41 (97.6%)
IPSS [30]: 28 (66.7%)
WPSS [31]: 19 (45.2%)
Other: 0 (0.0%)
2. Patient-Based Risk-Stratification
Do you use patient-based risk-stratification
scores in all MDS patients? 42 (97.7%)
Yes: 23 (54.8%)
No: 19 (45.2%)
When do you use patient-based
risk-stratification scores in MDS patients? 23 (53.5%)
At diagnosis: 18 (78.3%)
At transplantation: 17 (73.9%)
At progression: 13 (56.5%)
Other time points: 1 (4.3%)
Not at all: 1 (4.3%)
Which of the following scores do you use for
patient-based risk-stratification? 39 (90.7%)
HCT-CI (Hematopoietic Cell Transplantation-specific
comorbidity index) [32]: 26 (66.7%)
MDS-CI (MDS comorbidity index) [33]: 14 (35.9%)
CCI (Charlson comorbidity index) [34]: 12 (30.8%)
Other: 5 (12.8%)
3. Others
Do you use the prognostic model for
hypoplastic MDS [35]? 39 (90.7%)
I am not familiar: 15 (38.5%)
Yes: 13 (33.3%)
No: 11 (28.2%)
Do you use a combined risk-stratification tool? 42 (97.7%) No: 39 (92.9%)Yes: 3 (7.1%)
Do you use geriatric assessment tools to decide,
if elderly high-risk MDS patients with excess of
blasts are eligible for standard induction
chemotherapy?
42 (97.7%) No: 30 (71.4%)Yes: 12 (28.6%)
Do you use quality of life (QoL)





We received sufficient feedbacks for only eight of 21 questions (38%), while most of our questions
on infectious prophylaxis had to be dropped (Table 4 and Supplementary Materials Table S1). There was
insufficient agreement regarding the transfusion thresholds in all age groups regardless of comorbidities.
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Moreover, we found disagreement concerning the use of empirical primary infection prophylaxis
(11/41, 26.8%) in patients with severe neutropenia (<0.5 g/L) and insufficient agreement on which
compounds should be used, with exception of antimycotic agents (8/11, 72.7%).
Table 4. Supportive care.
Questions Feedback Performance
1. RBC and TC Transfusions
Hemoglobin threshold for RBC transfusion




4 (9.8%) < 60 g/L: 10 (24.4%) < 70 g/L: 17 (41.5%) < 80 g/L:
8 (19.5%) < 90 g/L: 1 (2.4%) < 100 g/L: 0 (0.0%)
Other: 1 (2.4%)
Hemoglobin threshold for RBC transfusion
for younger patients (<70 years) with




2 (4.9%) < 60 g/L: 0 (0.0%) < 70 g/L: 13 (31.7%) < 80 g/L:
19 (46.3%) < 90 g/L: 4 (9.8%) < 100 g/L: 1 (2.4%)
Other: 2 (4.9%)
Hemoglobin threshold for RBC transfusion




3 (7.3%) < 60 g/L: 0 (0.0%) < 70 g/L: 16 (39.0%) < 80 g/L:
18 (43.9%) < 90 g/L: 3 (7.3%) < 100 g/L: 0 (0.0%)
Other: 1 (2.4%)
Hemoglobin threshold for RBC transfusion
for elderly patients (≥70 years) with




1 (2.4%) < 60 g/L: 0 (0.0%) < 70 g/L: 2 (4.9%) < 80 g/L:
16 (39.0%) < 90 g/L: 14 (34.1%) < 100 g/L: 6 (14.6%)
Other: 2 (4.9%)
Platelet threshold for transfusion for
younger patients (<70 years) without signs
of bleeding or infection?
41 (95.3%)
Only in case of clinically relevant bleeding:
8 (19.5%) < 5 G/L: 8 (19.5%) < 10 G/L: 24 (58.5%) < 20 G/L:
0 (0.0%) < 30 G/L: 0 (0.0%)
Other: 1 (2.4%)
Platelet threshold for transfusion for elderly
patients (≥70 years) without signs of
bleeding or infection?
41 (95.3%)
Only in case of clinically relevant bleeding:
7 (17.1%) < 5 G/L: 8 (19.5%) < 10 G/L: 25 (61.0%) < 20 G/L:
1 (2.4%) < 30 G/L: 0 (0.0%)
Other: 0 (0.0%)
Platelet threshold for patients with signs
of infection? 41 (95.3%)
Only in case of clinically relevant bleeding:
1 (2.4%) < 5 G/L: 0 (0.0%) < 10 G/L: 20 (48.8%) < 20 G/L:
19 (46.3%) < 30 G/L: 1 (2.4%)
Other: 0 (0.0%)
2. Infection Prophylaxis
Do you provide empirical infection





Only after previous infection: 4 (9.8%)
3.3.2. Growth Factors
We received sufficient feedbacks for 17 of 22 questions (77.3%), while questions on dosing of growth
factors and neutrophil trigger for primary prophylaxis had to be dropped (Table 5 and Supplementary
Materials Table S1). We observed agreement only on the use of darbepoetin alfa (31/42, 75.6%) but not
on other recombinant erythropoiesis stimulating agents (ESA). There was insufficient agreement
concerning target hemoglobin concentration, the time for dose adaptation, and the maximum
weekly dose of recombinant ESA or darbepoietin alpha. We found disagreement on the use of
granulocyte colony-stimulating factor (G-CSF) (10/41, 24.4%) or lenalidomide (LEN) (12/40, 30%) in
ESA non-responders. There was clear disagreement on G-CSF for primary infection prophylaxis in
neutropenic patients (4/41, 9.8%) but agreement on secondary prophylaxis in neutropenic patients
after a history of fever (25/41, 61%), using a neutrophil trigger of <0.5 g/L (22/25, 88%). Insufficient
agreement was found on the use of pegylated G-CSF (10/25, 40%). Concerning thrombopoietin-receptor
agonists (TPO-RA), insufficient agreement was found on the type of agent, the threshold (tendency
<20 G/L) and the appropriate indication in MDS patients (tendency for lower-risk MDS, concomitant
ITP and hypoplastic MDS).
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Table 5. Growth factors.
Questions Feedback Performance
1. Erythropoietin Stimulating Agents (ESA)
Do you agree with the ELN 2013 recommendations
for ESA treatment in MDS patients [1]? 41 (95.3%)
Yes: 34 (82.9%)
I am not familiar: 4 (9.8%)
No: 3 (7.3%)
Which ESA do you prefer? 41 (95.3%)
Darbepoetin alfa (Aranesp®): 31 (75.6%)
No preference: 5 (12.2%)
Epoetin alfa (e.g., Eprex®): 3 (7.3%)
Epoetin beta (e.g., Recormon®): 2 (4.9%)
What is the Hemoglobin concentration you






After what time do you adapt the initial








What is the maximum dose you use in order to test










What is the maximum dose you use in order to test








Do you add G-CSF in non-responders? 41 (95.3%) No: 31 (75.6%)Yes: 10 (24.4%)
Do you try lenalidomide in non-responders? 40 (93%)
Only in del(5q): 22 (55%)
Yes: 12 (30%)
No: 6 (15%)
2. Granulocyte-Colony-Stimulating Factor (G-CSF)
Do you use G-CSF for primary infection prophylaxis
in neutropenic patients? 41 (95.3%)
No: 37 (90.2%)
Yes: 4 (9.8%)
Do you use G-CSF for secondary infection
prophylaxis in neutropenic patients that experienced
neutropenic fever?
41 (95.3%) Yes: 25 (61%)No: 16 (39%)
What is your neutrophil trigger for secondary
infection prophylaxis? 25 (58.1%)
<1.5 G/L: 0 (0.0%)
<1.0 G/L: 2 (8%)
<0.5 G/L: 22 (88%)
<0.2 G/L: 1 (4%)
Do you use pegylated G-CSF? 26 (60.5%) No: 16 (61.5%)Yes: 10 (38.5%)
3. Thrombopoietin-Receptor Agonist (TPO-RA)
Do you use TPO-RA in thrombopenic MDS patients?
(multiple answers possible) 40 (93%)
In MDS with concomitant ITP: 18 (45%)
In hypoplastic MDS: 15 (37.5%)
Not at all: 13 (32.5%)
In lower-risk MDS (IPSS low, int-1): 12 (30%)
As secondary bleeding prophylaxis: 6 (15%)
In higher-risk MDS (IPSS int-2, high): 2 (5%)
As primary bleeding prophylaxis: 1 (2.5%)
Which TPO-RA do you prefer? 26 (60.5%)
I do not have a preference: 11 (42.3%)
Romiplostim (Nplate®): 8 (30.8%)
Eltrombopag (Revolade®): 7 (26.9%)
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Table 5. Cont.
Questions Feedback Performance
Which platelet count trigger do you use for










100 mg (50 mg asian)/day: 7 (25.9%)
200 mg (100 mg asian)/day: 6 (22.2%)
300 mg (150 mg asian)/day: 5 (18.5%)




10 ug/kg/week: 14 (51.9%)
5 ug/kg/week: 2 (7.4%)
Other: 3 (11.1%)
3.3.3. Disease-Modifying Treatment
We received sufficient feedbacks for 28 of 40 questions (70%), while questions on thromboembolic
prophylaxis with LEN, treatment modalities of immunosuppressive treatment (IST) and dose
adjustments of HMA had to be dropped (Table 6 and Supplementary Materials Table S1). We found
a high agreement on treatment of MDS del(5q) patients with LEN (39/40, 97.5%), agreement on
treatment with LEN of patients with one or two additional cytogenetic alteration except chromosome
7 (29/38, 76.3%) and agreement on assessment of TP53 mutational status before LEN start (25/38, 65.8%)
and in LEN non-responders (24/38, 63.2%). Insufficient agreement was found on previous assessment
of ESA responsiveness (25/38, 65.8%) and the use of LEN in non-del(5q) MDS patients (13/39; 33.3%).
The most frequent dosing schedule for LEN was 10 mg d1–d21 (65.8%). The participants disagreed on
combining LEN with ESA (10/38, 26.3%) and using thromboembolic prophylaxis (11/39, 28.2%).
Table 6. Disease-modifying treatment.
Questions Feedback Performance
1. Lenalidomid (LEN)
Do you use LEN in del(5q) MDS patients? 40 (93%) Yes: 39 (97.5%)No: 1 (2.5%)
Which initial LEN dose do you use in MDS patients? 38 (88.4%)
10 mg d1–21: 26 (68.4%)
10 mg d1–28: 7 (18.4%)
5 mg d1–21: 2 (5.3%)
5 mg d1–28: 2 (5.3%)
Other dose: 1 (2.6%)
Do you assess EPO responsiveness before LEN? 38 (88.4%) Yes: 25 (65.8%)No: 13 (34.2%)
Do you combine LEN and EPO? 38 (88.4%) No: 28 (73.7%)Yes: 10 (26.3%)
Do you use LEN in del(5q) with additional
cytogenetic alterations (except alterations of
chromosome 7)?
38 (88.4%) Yes: 29 (76.3%)No: 9 (23.7%)
How many cytogenetic alterations would you accept
beside del(5q) to treat with LEN? 29 (67.4%)
1 additional alteration: 12 (41.4%)
2 additional alterations: 8 (27.6%)
3 additional alterations: 2 (6.9%)
More than 3 additional alterations: 7 (24.1%)
Do you check TP53 mutational status before
prescribing LEN? 38 (88.4%)
Yes: 25 (65.8%)
No: 13 (34.2%)
Do you check TP53 mutational status in
non-responders to LEN? 38 (88.4%)
Yes: 24 (63.2%)
No: 14 (36.8%)
Do you use LEN in non-del(5q) MDS patients? 39 (90.7%) No: 26 (66.7%)Yes: 13 (33.3%)
Do you provide thromboembolic prophylaxis when
prescribing LEN? 39 (90.7%)
No: 28 (71.8%)
Yes: 11 (28.2%)
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Table 6. Cont.
Questions Feedback Performance
2. Immunosuppressive Treatment (IST)




Do you try ATG/CsA in MDS patients with other
than hypoplastic MDS? 39 (90.7%)
No: 37 (94.9%)
Yes: 2 (5.1%)
Is ATG/CsA your first choice in younger patients
(<40 years) with hypoplastic MDS? 28 (65.1%)
Yes: 15 (53.6%)
No: 13 (46.4%)
Do you always combine CsA with ATG in elderly
patients (>70 years) with hypoplastic MDS? 28 (65.1%)
No: 20 (71.4%)
Yes: 8 (28.6%)
Do you use steroids in MDS patients? 39 (90.7%) No: 25 (64.1%)Yes: 14 (35.9%)
3. Hypomethylating Agents (HMA)
What minimal risk category do you require for
treatment with HMA? 39 (90.7%)
Intermediate (IPSS: Int-1; IPSS-R: Intermediate):
25 (64.1%)
High (IPSS: Int-2, high; IPSS-R: high, very high):
11 (28.2%)
IPSS score does not influence my decision for
HMA: 3 (7.7%)
Low (IPSS: Low; IPSS-R: Very Low & Low):
0 (0.0%)
Are severe thrombopenia (<20 G/L), anemia (<70 g/L)
or neutropenia (<0.5 G/L) an indication for treatment
irrespective of IPSS or IPSS-R?
39 (90.7%) Yes: 25 (64.1%)No: 14 (35.9%)
Which HMA do you preferably use for
MDS patients? 39 (90.7%)
5-Azacytidine (AZA, Vidaza®): 38 (97.4%)
Decitabine (DEC, Dacogen®): 1 (2.6%)
What is the standard dose you use for
5-Azacytidine (AZA)? 38 (88.4%)
100 mg/m2 d1–d5: 24 (63.2%)
75 mg/m2 d1–d7: 14 (36.8%)
Other: 0 (0.0%)
Do you reduce the dose in frail patients with
non-high-risk MDS? 39 (90.7%)
No: 22 (56.4%)
Yes: 17 (43.6%)
Do you reduce the dose in frail patients with
high-risk MDS? 39 (90.7%)
No: 30 (76.9%)
Yes: 9 (23.1%)
To which extent do you reduce the dose of HMA in
frail MDS patients? 37 (86%)
75% of standard dose: 14 (37.8%)
50% of standard dose: 6 (16.2%)
25% of standard dose: 6 (16.2%)
Other dose reduction: 11 (29.7%)
Do you perform BM aspiration in MDS patients
under HMA therapy at best response? 39 (90.7%)
Not on a regular basis: 23 (59%)
Yes: 8 (20.5%)
No: 8 (20.5%)
Do you perform BM aspiration in MDS patients
under HMA therapy in stable patients after
4–6 cycles?
39 (90.7%)
Not on a regular basis: 19 (48.7%)
Yes: 14 (35.9%)
No: 6 (15.4%)
Do you perform BM aspiration in MDS patients
under HMA therapy at progression? 39 (90.7%)
Yes: 35 (89.7%)
Not on a regular basis: 4 (10.3%)
No: 0 (0.0%)
Do you reduce the dose of HMA in responding
patients after 6 cycles? 39 (90.7%)
No: 24 (61.5%)
Only in patients with side effects: 16 (41%)
Yes: 1 (2.6%)
Do you extend the interval of HMA application in
responding patients? 39 (90.7%)
No: 17 (43.6%)
Yes: 9 (23.1%)
Only in patients with side effects: 13 (33.3%)
Do you think that stable disease after 6 cycles in
high-risk MDS patients can be considered
as response?
39 (90.7%) Yes: 26 (66.7%)No: 13 (33.3%)
We found agreement on using anti-thymocyte globulin (ATG) with cyclosporin A (CsA) as IST in
patients with hypoplastic MDS (28/39, 71.8%) but insufficient agreement on the first line treatment
in younger patients (<40 years) (15/28, 53.6%). Disagreement was found on a strict combination of
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ATG/CsA in elderly patients (8/28, 28.6%) and strong disagreement on its use in MDS patients with
other than hypoplastic MDS (2/39, 5%). There was insufficient agreement on the use of steroids in
MDS patients (14/39, 35.9%) with potential indications comprising immune-thrombocytopenia and
autoimmune hemolytic anaemia.
Concerning the requirements for initiation of treatment with HMA, we found agreement on an
intermediate IPSS-R as minimal disease-based risk score (25/39, 64.1%), as well as the occurrence of
severe thrombocytopenia (<20 G/L), anemia (<70 g/L) or neutropenia (<0.5 G/L) (25/39, 64.1%).
The preferred HMA was azacytidine (38/39, 97.4%) prescribed most frequently at 100 mg/m2
d1–d5 (63.2%) compared to 75 mg/m2 d1–d7 (37.8%). Insufficient agreement was found on dose
reduction in frail patients with non-high risk (17/39, 43.6%) and disagreement for dose reduction in
high-risk MDS patients (9/39, 23.1%). We found agreement on performing bone-marrow assessment
at the emergence of signs for progression (35/39, 89.7%), insufficient agreement on stable patients
after 4–6 cycles (14/39, 35.9%) and disagreement on the documentation of best response (8/39, 20.5%).
Disagreement was also found on dose reduction after six cycles in responding patients (1/39, 2.6%) or
extension of the treatment intervals (9/39, 23.1%), both of which might be reserved for patients with
side effects.
3.3.4. Allogeneic Hematopoietic Stem Cell Transplantation
Only six participants declared experience with allo HSCT, which reduced the representativeness
of our survey for this treatment option. We received more than 50% feedbacks for 14 of 22 questions
(63.6%) (Table 7 and Supplementary Materials Table S1).
Table 7. Allogeneic hematopoietic stem cell transplantation (n = 6).
Questions Feedback Performance
Do you perform allo HSCT at your center? 40 (93%) Yes: 6 (15%)No: 34 (85%)
1. Indications
At what risk category do you envisage allo HSCT? 6 (100%)
High (IPSS: Int-2, high;
IPSS-R: high, very high): 5 (83.3%)
Intermediate (IPSS: Int-1; IPSS-R: Intermediate): 1 (16.7%)
Low (IPSS: Low; IPSS-R: Very Low & Low): 0 (0.0%)
IPSS score does not influence my decision for allo HSCT:
0 (0.0%)
What is the maximum age to envisage allo HSCT? 6 (100%)
65–69 years: 1 (16.7%)
70–74 years: 5 (83.3%)
>75 years: 0 (0.0%)
Which HCT-CI/MDS-CI score precludes allo HSCT? 6 (100%)
HCT-CI/MDS-CI ≥3 (less fit): 4 (66.7%)
HCT-CI/MDS-CI 1-2 (intermediate fit): 2 (33.3%)
HCT-CI/MDS-CI 0 (fit): 0 (0.0%)
2. Induction Therapy
What is your preferred induction therapy for fit MDS
patients (HCT-CI/MDS-CI: 0) with <5% BM-blasts
eligible for allo HSCT?
6 (100%)
HMA: 3 (50.0%)
No induction, upfront allo HSCT: 2 (33.3%)
Standard AML induction chemotherapy (e.g., 3 + 7): 1 (16.7%)
Other: 0 (0.0%)
What is your preferred induction therapy for fit MDS
patients (HCT-CI/MDS-CI: 0) with >5% BM-blasts
eligible for allo HSCT?
6 (100%)
Standard AML induction chemotherapy (e.g., 3 + 7): 5 (83.3%)
HMA: 1 (16.7%)
No induction, upfront allo HSCT: 0 (0.0%)
Other: 0 (0.0%)
What is your preferred induction therapy for
intermediate fit MDS patients (HCT-CI/MDS-CI: 1–2)
with <5% BM-blasts eligible for allo HSCT?
6 (100%)
HMA: 3 (50.0%)
No induction, upfront allo HSCT: 3 (50.0%)
Standard AML induction chemotherapy (e.g., 3 + 7): 0 (0.0%)
Other: 0 (0.0%)
What is your preferred induction therapy for
intermediate fit MDS patients (HCT-CI/MDS-CI: 1-2)
with >5% BM-blasts eligible for allo HSCT?
6 (100%)
HMA: 4 (66.7%)
Standard AML induction chemotherapy (e.g., 3 + 7): 2 (33.3%)
No induction, upfront allo HSCT: 0 (0.0%)
Other: 0 (0.0%)




What is your preferred conditioning strategy for fit
MDS patients (HCT-CI/MDS-CI: 0) with <5%
BM-blasts eligible for allo HSCT?
6 (100%) RIC: 3 (50.0%)MAC: 3 (50.0%)
What is your preferred conditioning strategy for fit
MDS patients (HCT-CI/MDS-CI: 0) with >5%
BM-blasts eligible for allo HSCT?
6 (100%) RIC: 3 (50.0%)MAC: 3 (50.0%)
What is your preferred conditioning strategy for
intermediate fit MDS patients (HCT-CI/MDS-CI: 1–2)
with <5% BM-blasts eligible for allo HSCT?
6 (100%) RIC: 6 (100.0%)MAC: 0 (0.0%)
What is your preferred conditioning strategy for
intermediate fit MDS patients (HCT-CI/MDS-CI: 1–2)
with >5% BM-blasts eligible for allo HSCT?
6 (100%) RIC: 5 (83.3%)MAC: 1 (16.7%)
4. Others
Do you perform autologous HSCT as a consolidation
therapy for MDS patients without a suitable donor? 6 (100%)
No: 6 (100%)
Yes: 0 (0.0%)
Do you consider molecular risk factors such as TP53
or RAS for the decision to transplant or not? 6 (100%)
Yes: 5 (83.3%)
No: 1 (16.7%)
There was agreement on the maximum age for transplantation (70–74 years), the consideration of
patients with only high-risk disease (IPSS intermediate 2 and IPSS-R high, very high) and high-risk
molecular risk factors for the indication of allo HSCT (all 5/6, 83.3%). Insufficient agreement was
found on the question, if intermediate fit (2/6, 33.3%) or only unfit patients (4/6, 66.7%) (according
HCT-CI and MDS-CI) should be precluded from allo HSCT. Furthermore, there was agreement on the
treatment with standard induction chemotherapy for fit patients with excess of blast (5/6, 83.3%) and
full agreement on the use of reduced-intensity conditioning regimen (RIC) for intermediate fit patients
with <5% BM blasts before transplantation (6/6, 100%). We found a high disagreement on performing
autologous HSCT as consolidation treatment for MDS patients without a suitable donor (0/6, 0%).
4. Discussion
With our survey, we have captured the current perception among hemato-oncologists of what
they consider a recommended management of adult MDS patients in Switzerland. Here we mainly
focused on areas with uncertain agreement, which can be addressed for future improvements.
In the diagnostic domain, the participants expressed their uncertainty in using the diagnostic
terms of CHIP, CCUS, ICUS/IDUS. This probably reflects insufficient familiarity with these recent
terms, their questionable relevance in daily clinical practice and issues with reimbursement of NGS in
patients with mild cytopenia. The uncertainty in using bone marrow examination and cytogenetic
to assess response to HMA is most likely due to limited treatment alternatives after HMA failure in
elderly patients. Moreover, the role of flowcytometry for diagnosis and prognosis in MDS remains
controversial, not only in our survey but also among international MDS experts [36]. Flowcytometry
requires a high degree of infrastructural and personnel resources, standardization and might be replaced
by NGS for the identification of clonality in uncertain cases. Recording a pedigree, using screening
questionnaires and referral for genetic counseling seem to be reasonable in patients with suspected
germ-line predisposition but did not reach sufficient agreement in our survey, similarly as we have
observed among international MDS experts [36]. However, due to the simplicity of an adequate
history taking and significant consequences for allo HSCT (donor selection and conditioning intensity),
we would like to emphasize the importance of correctly diagnosing familial cases of MDS.
In the risk-stratification domain, disease-based risk-stratification with IPSS did not reach sufficient
agreement, in contrast to IPSS-R. This seems to be surprising, as IPSS is required for appropriate
treatment allocation according to official labels derived from remote clinical trials, even though,
IPSS-R performs much better for risk-stratification [13]. Therefore, both seem to have their justification.
There is a broad uncertainty in using patient-based risk scores, combined risk-stratification, geriatric and
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quality of life (QoL) assessment, which is in line with our observation made with international MDS
experts [36]. Even though, these are relevant aspects for the management of elderly MDS patients,
there is an unmet need in finding a consensus for their appropriate use in daily clinical practice.
Regarding the therapy domain, most questions on infectious prophylaxis received insufficient
feedbacks and participants expressed disagreement concerning the use of empirical primary infection
prophylaxis. This may reflect the lack of available evidence from appropriately designed clinical trials
leading to insufficient consensus on this topic. In addition, due to concerns of bacterial resistance there
is a general reluctance in using antibiotic prophylaxis. Regarding treatment with ESAs in lower-risk
MDS patients, we found agreement on the use of darbepoetin alfa but not for other recombinant
ESAs. This might be due to the fact that darbepoietin alpha is the only ESA reimbursed for the MDS
indication in Switzerland and needs applications only every 2–3 weeks [37]. However, there is no
formal proof of its superiority in efficacy or safety compared to other ESAs. We also found uncertainty
concerning target hemoglobin level, dosing schedules and dose adjustments in our survey, which might
reflect insufficient standardization of ESA treatment and assessment of response. Concerning TPO-RA,
we found insufficient agreement for the appropriate indication in MDS, the preferred agent and
the trigger of platelet counts required for initiation of treatment. While TPO-RA have shown to
increase platelet counts, reduce the number of platelet transfusions and severity of bleeding episodes in
randomized controlled trials [38,39], the overall clinical benefit remains unclear and the treatment is still
off-label. Furthermore, initial concerns of potential disease progression and leukemic transformation
seem not to be justified but remain potential reasons for reluctance [40]. We found low feedbacks on
thromboembolic prophylaxis with LEN, treatment modalities of IST and dosing adjustments of HMA,
which may be explained by insufficient data from clinical trials. Furthermore, the insufficient agreement
on the first line treatment in younger patients (<40 years) and disagreement for strict combination
of ATG/CsA in elderly patients with hypoplastic MDS most likely reflects the lack of experience and
standardized approaches with this rare MDS entity. The low feedback rate regarding allo HSCT from
only six knowledgeable participants limits the interpretation of these results. We observed insufficient
agreement for the decision, if intermediate fit or only unfit patients (according HCT-CI and MDS-CI)
should be precluded from allo HSCT, which underlines the lack of evidence for this question. The fact
that none of the participants gave any preference for the induction or consolidation treatment regimen
before allo HSCT reflects previous observations we made during the GBI development [36].
The strengths of our study was the wide range of questions, covering many aspects of clinical
care of MDS patients. Moreover, the participants were affiliated to different types of health care centers
and the determination of agreement/disagreement was standardized. The main limitation is the low
number of participants (overall feedback-rate 14%), which is, however, inherent to web-based surveys
among physicians [41]. Our survey reflects a national perspective of physicians that are interested in
MDS treatment, who were mainly hematologists <50 years of age, associated to the Swiss hematology
association and practicing in secondary and tertiary centers with few participants from primary centers.
This may limit the extrapolation to all of Switzerland and other countries. It is also known form other
studies that tertiary centers treat younger patients with more intensive treatments, which translated into
a reduced mortality in academic compared to community-based hospitals [42] Moreover, the survey
was not designed to provide a feedback to the participants, discuss the results and repeat the assessment.
This is usually done in a more structured RAND DELPHI consensus finding process, as we have
previously adopted for the GBI development [36,43] As such, surveys remain generally biased by the
limited number and the composition of the participants. Finally, and most importantly, agreeing or
dis-agreeing with certain questions does not necessarily mean that the clinician’s attitude will be
translated into practice.
The main reasons why clinicians may not follow G/Rs include awareness, familiarity,
agreement with the contents, insufficient evidence with questionable clinical relevance but also potential
issues regarding reimbursement [44]. There are also potential patient-based factors that interfere
with recommended management such as advanced comorbidities and frailty, acceptance of treatment
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and compliance. Moreover, also provider and infrastructural barriers may influence adherence,
such as limited time and personnel (physicians, nurses, multidisciplinary care teams), inadequate
organization (isolation ward, handling of cytotoxic drugs, interdisciplinary boards, emergency services,
standard operating procedures), barriers for cooperation (exchange of knowledge, multi-institutional
care networks, access to clinical trials) as well as financial resources. However, reasons for adherence/
non-adherence and their impact on relevant patient centered outcomes remain obscure and have not
been sufficiently investigated. This may be caused by the fact, that process-based elements for quality
of care and patient centred outcomes are not systematically measured in daily clinical routine [45,46].
For this, quality indicators need to be defined as “measurable elements of practice performance for
which there is evidence or consensus that they can be used to assess and change the quality of care
provided” [45]. Quality indicators are usually extracted from published, evidence-based guidelines by
a structured selection and consensus process, and are referred to as guideline-based indicators (GBIs).
Motivated by all these relevant limitations, our study group set out to develop a first consensus on
GBIs, addressing best practice performance, outcomes and structural resources in collaboration with
internationally acknowledged experts [36,47,48]. Such GBIs have been recently published for adult
MDS patients and will be prospectively validated as standardized instrument in the I-CARE for MDS
Study with the goal to assess, compare and foster good quality of care.
5. Conclusions
We performed a survey in hemato-oncologists focusing on recommended care in adult MDS
patients in Switzerland. We identified areas for improvement in the domains of diagnosis,
risk-stratification and therapy, which should be further addressed with clinical trials, information,
and guiding documents. Identifying reasons for adherence/non-adherence to G/Rs is important to
understand the clinical challenges for their implementation, areas with insufficient evidence and
potential fields of action. A standardized assessment of relevant GBIs may help to define specific
measures to improve daily care of MDS patients within clinical development cycles.
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